РЕЗОЛЮЦИЯ ПО ИТОГАМ ЭКСПЕРТНОГО СОВЕТА ПО ПРОБЛЕМАМ ДИФФЕРЕНЦИРОВАННОГО ПОДХОДА К ТЕРАПИИ СНМП


DOI: https://dx.doi.org/10.18565/urology.2019.4.6-8


Литература


1. Пушкарь Д.Ю., Раснер П.И. Харчилава Р.Р. Симптомы нижних мочевых путей и доброкачественная гиперплазия предстательной железы. Урология, 2016;2(Приложение ):4–19.

2. Abrams P., et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. 21: 167.

3. Martin S.A., Haren M.T., Marshall V.R., Lange K., Wittert G.A. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol. 2011;29(2):179–184. doi : 10,1007 / s00345-010-0605-8.

4. Irwin D. et al. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study. European Urology. 2007;50(6):1306–1315.

5. Guess H.A. Epidemiology and natural history of benign prostatic hyperplasia. Urol. Clin. North. Аm. 1995;22:247–261.

6. EAU 2019 Доступно на http://uroweb.org/guideline/treatment-of-non-neurogenicmale-luts/

7. Kaplan SA. New data on tolterodine: do recent findings dispel questions about treating overactive bladder in men? European Urology 2007;6(Suppl.):10–16.

8. Antunes A.A. Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate? J Urol. 2015;193(6):2028–2032. Doi:10.1016/j.juro.2014.12.095.Epub 2015 Jan 9.

9. Milsom I.P. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU International. 2001;87:760–766.

10. Michel M.C., et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1:332.

11. Drake M.J. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33:622.

12. Benner J.S. et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–1282.

13. Wagg A. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. 2012 BJU INTERNATIONAL . Doi:10.1111/j.1464-410X.2012.11023.x

14. Takasu T. et al. Effect of (R)-2-(2-Aminothiazol-4-yl)-4_-{2-

15. Nitti V.W. et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. J Clin Pract. Doi: 10.1111/ijcp.12194.

16. Kakizaki H. et al. Efficacy and safety of add-on mirabegron vs. placebo to tamsulosin in men with overactive bladder symptoms (match study). The Journal of Urology. 2018;199(4S, Suppl.).

17. Ichihara K. et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193(3):921–926. Doi: 10.1016/j.juro.2014.09.091. Epub 2014 Sep 22.

18. Tubaro A. et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol 2017;9(6):137–154. Doi: 10.1177/1756287217702797.

19. Haab F. et al. Long-TermOpen-Label SolifenacinTreatment Associated with Persistence withTherapy in Patients with Overactive Bladder Syndrome. Eur Urol. 2005; 47: 376–384.

20. Drake M. et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). European Urology. 2016;70:136–145.

21. Abrams P et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–588. Doi: 10.1016/j.eururo.2014.02.012.

22. Gratzke C. at al. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018; 74(4):501–509. Doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1.


Бионика Медиа